Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SanBio Co ( (JP:4592) ) has shared an announcement.
SanBio Company Limited reported its consolidated financial results for the nine months ending October 31, 2025, showing a continued net loss with operating and ordinary income also in negative figures. The company’s financial position weakened compared to the previous period, with a significant decrease in total assets and net assets, reflecting ongoing challenges in its operations and market positioning.
The most recent analyst rating on (JP:4592) stock is a Sell with a Yen1010.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Company Limited is a company listed on the Tokyo Stock Exchange, primarily operating in the biotechnology industry. The company focuses on developing regenerative cell therapies to address unmet medical needs, particularly in the field of neurological disorders.
YTD Price Performance: 119.31%
Average Trading Volume: 2,911,653
Technical Sentiment Signal: Sell
Current Market Cap: Yen128.5B
For detailed information about 4592 stock, go to TipRanks’ Stock Analysis page.